Reply to A. Addeo and A. Bahl

Affiliations

¹ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY scherh@mskcc.org.
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Janssen Research & Development, Menlo Park, CA.
⁴ Janssen Research & Development, San Diego, CA.
⁵ The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

Comment

Howard I Scher et al. J Clin Oncol. 2016.

. 2016 Feb 1;34(4):387-8.

doi: 10.1200/JCO.2015.64.6562. Epub 2015 Nov 23.

¹ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY scherh@mskcc.org.
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Janssen Research & Development, Menlo Park, CA.
⁴ Janssen Research & Development, San Diego, CA.
⁵ The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

No abstract available

Comment on

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS. Scher HI, et al. J Clin Oncol. 2015 Apr 20;33(12):1348-55. doi: 10.1200/JCO.2014.55.3487. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800753 Free PMC article. Clinical Trial.
Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
Addeo A, Bahl A. Addeo A, et al. J Clin Oncol. 2016 Feb 1;34(4):387. doi: 10.1200/JCO.2015.62.8537. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598758 No abstract available.